Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

Abstract: A field bus module for the operation of actuators and/or sensors with at least one device interface for the connection of a sensor and/or actuator, with at least one field bus interface for connection to a field bus system, and with a processing device for receiving and processing and sending field bus telegrams and also for making available control commands, especially safety-oriented control commands, to the device interface depending on incoming field bus telegrams wherein the processing device is configured to process in different operating modes sensor data that can be made available at the device interface and/or field bus telegrams that can be made available at the field bus interface, wherein an operating mode memory is allocated to the processing device for the optional provision of one of at least two different operating mode data sets at the processing device depending on an incoming field bus telegram.

Abstract: The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as siRNA.

Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.

Abstract: The invention relates to the treatment of the wastewater from isophorone production (IP) by high-pressure wet oxidation.

Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.

Abstract: Treatment of the wastewater from isophorone production comprising neutralization, filtration and a downstream chemical oxidation process and subsequent reduction. The invention relates to treatment of the wastewater from isophorone (IP) production comprising neutralization, filtration and a downstream chemical oxidation process and subsequent reduction.

Abstract: A device connectable to a three-phase network, wherein the device includes a capacitor, a secondary coil, a diode and, per phase, a conductor and a circuit, where a secondary-side coil is connected in parallel to the capacitor via the diode, the circuit is configured such that a resistor is located in a conductor, a first capacitor is connected parallel to the resistor, a serial circuit of a first primary-side coil is connected in parallel to the first capacitor, energy transfer occurs from a first primary-side coil to a second primary-side coil and to the secondary-side coil, a second capacitor is connected in parallel to the second primary-side coil, the second capacitor is connected to the source connection of a self-conducting field effect transistor, and the gate connection of the self-conducting field effect transistor is connected to the second capacitor to provide an improved internal power supply for the device.

Abstract: There is described a method for evaluating a level of noise in a biosignal the method comprising receiving a time signal representative of a biological activity, the time signal comprising a biological activity component and a noise component; determining a modulation spectrum for the time signal, the modulation spectrum representing a signal frequency as a function of a modulation frequency; from the modulation spectrum determining a first amount of modulation energy corresponding to the biological activity component and a second amount of modulation energy corresponding to the noise component determining an indication of the level of noise using the first and second amounts of modulation energy; and outputting the indication of the level of noise.

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.

Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.

Abstract: A device for protecting a user includes a first current path including a first and second conduit, and a monitoring device for detecting an imminent overload of the electric user. In an embodiment, the monitoring device includes a first temperature measurement unit, a support, an evaluation unit and a first transducer to produce an electrically conductive connection between the first and second conduits of the first current path. The first temperature measurement unit is, electrically insulated from the first transducer and includes a first temperature sensor. An additional electrically insulating material; is arranged on a first lateral surface of the support between the first transducer and the support and the first temperature sensor is arranged on the support to detect a temperature of the first transducer. The evaluating unit is configured to detect an imminent overload at the user on the basis of temperatures detected by the first temperature sensor.

Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.

Abstract: A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.

Abstract: A method is described for manufacturing a solenoid valve, in particular a fuel injector, the solenoid valve having a valve needle which is movably guided in the axial direction, a magnet core and an armature which is situated axially diametrically opposed to the magnet core, the armature being situated on the valve needle, the armature having a first base material and a first reinforcing element and the magnet core having a second base material and a second reinforcing element. The method has one method step. The first reinforcing element is applied to the first base material and/or the second reinforcing element is applied to the second base material during the method step with the aid of molten bath spraying or with the aid of cold gas spraying.

Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.